Eli Lilly and Company (NYSE:LLY) Trading 3.6% Higher – Should You Buy?

Eli Lilly and Company (NYSE:LLY)’s share price rose 3.6% during trading on Tuesday . The stock traded as high as $924.14 and last traded at $918.12. Approximately 3,428,457 shares changed hands during trading, an increase of 8% from the average daily volume of 3,173,018 shares. The stock had previously closed at $886.63.

Key Stories Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Lilly agreed to acquire Centessa Pharmaceuticals for $38/share in an upfront deal (~$6.3B) with potential milestone payments that raise the price to ~ $7.8B — adding OX2R agonists (cleminorexton) that target narcolepsy and other sleep‑wake disorders and immediately expanding Lilly’s neuroscience/sleep portfolio. The acquisition requires regulatory and shareholder approvals. Eli Lilly to buy Centessa Pharma in $6.3 billion deal
• Positive Sentiment: Lilly expanded its AI drug‑discovery partnership with Insilico Medicine in a deal potentially worth up to $2.75B, giving Lilly exclusive commercialization rights to AI‑discovered candidates — a strategic move to accelerate R&D, lower discovery timelines and broaden future product flow. Eli Lilly extends partnership with Insilico Medicine for AI-powered drug discovery
• Positive Sentiment: Recent earnings and guidance show strong cash flow and high margins (recent quarter beat and FY guidance raised), supporting Lilly’s ability to fund M&A and large R&D investments without straining the balance sheet. This underpins investor confidence in funding the Centessa buy and AI deals. Eli Lilly and Company financial snapshot
• Neutral Sentiment: Analyst activity remains constructive: Jefferies reiterated a Buy and some firms maintain upside targets, while others made minor price‑target tweaks — signaling continued bullish institutional view but varied near‑term valuations. Jefferies Remains a Buy on Eli Lilly
• Neutral Sentiment: Industry/partner signaling: a former Lilly executive was nominated to Lonza’s board — a peripheral personnel development that may help industry relationships but is unlikely to move LLY shares materially. Lonza strengthens board with nomination of former Eli Lilly executive
• Negative Sentiment: Lilly is pressing for higher NHS pricing and changes to U.K. rebate rules to restart investment there — a negotiation that could provoke political/payer pushback and introduce reimbursement risk in an important market. Eli Lilly seeks higher NHS drug prices, rebate overhaul

Analysts Set New Price Targets

A number of equities analysts recently weighed in on LLY shares. Argus lifted their price objective on shares of Eli Lilly and Company from $930.00 to $1,200.00 and gave the company a “buy” rating in a research report on Monday, February 9th. HSBC downgraded shares of Eli Lilly and Company from a “hold” rating to a “reduce” rating and cut their price objective for the stock from $1,070.00 to $850.00 in a research report on Tuesday, March 17th. Loop Capital set a $1,200.00 target price on shares of Eli Lilly and Company in a report on Tuesday, February 10th. Royal Bank Of Canada started coverage on shares of Eli Lilly and Company in a research note on Tuesday, February 24th. They set an “outperform” rating and a $1,250.00 price target on the stock. Finally, Barclays started coverage on shares of Eli Lilly and Company in a report on Thursday, February 19th. They set an “overweight” rating and a $1,350.00 price target for the company. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, four have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $1,221.26.

Eli Lilly and Company Price Performance

The stock has a fifty day moving average of $1,004.20 and a two-hundred day moving average of $965.80. The stock has a market cap of $867.46 billion, a price-to-earnings ratio of 40.01, a price-to-earnings-growth ratio of 1.02 and a beta of 0.40. The company has a quick ratio of 1.19, a current ratio of 1.58 and a debt-to-equity ratio of 1.54.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Wednesday, February 4th. The company reported $7.54 EPS for the quarter, beating analysts’ consensus estimates of $7.48 by $0.06. The company had revenue of $19.29 billion during the quarter, compared to the consensus estimate of $17.85 billion. Eli Lilly and Company had a return on equity of 102.94% and a net margin of 31.66%.Eli Lilly and Company’s quarterly revenue was up 42.6% compared to the same quarter last year. During the same quarter last year, the company earned $5.32 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. On average, equities research analysts anticipate that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Institutional Trading of Eli Lilly and Company

Institutional investors have recently added to or reduced their stakes in the stock. Maryland Capital Advisors Inc. acquired a new stake in shares of Eli Lilly and Company during the 4th quarter valued at approximately $25,000. Osbon Capital Management LLC acquired a new stake in shares of Eli Lilly and Company in the 4th quarter worth approximately $25,000. Vermillion & White Wealth Management Group LLC increased its stake in Eli Lilly and Company by 84.2% in the 3rd quarter. Vermillion & White Wealth Management Group LLC now owns 35 shares of the company’s stock valued at $27,000 after purchasing an additional 16 shares in the last quarter. Evolution Wealth Management Inc. acquired a new position in Eli Lilly and Company during the second quarter worth $29,000. Finally, Steph & Co. raised its holdings in Eli Lilly and Company by 290.0% during the third quarter. Steph & Co. now owns 39 shares of the company’s stock worth $30,000 after purchasing an additional 29 shares during the last quarter. Hedge funds and other institutional investors own 82.53% of the company’s stock.

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.